Compare · CAH vs SCNX
CAH vs SCNX
Side-by-side comparison of Cardinal Health Inc. (CAH) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CAH is the larger of the two at $55.33B, about 3261.2x SCNX ($17.0M).
- CAH has been more active in the news (30 items in the past 4 weeks vs 4 for SCNX).
- CAH has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- Cardinal Health Inc.
- Scienture Holdings Inc.
- Price
- -
- -
- Market cap
- $55.33B
- $17.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 30
- 4
- Recent ratings
- 25
- 0
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Latest CAH
- Chief Accounting Officer Scherer Mary C. sold $546,473 worth of shares (2,302 units at $237.39), decreasing direct ownership by 45% to 2,811 units (SEC Form 4)
- Chief Executive Officer Hollar Jason M. sold $29,375,516 worth of shares (124,529 units at $235.89), decreasing direct ownership by 40% to 190,603 units (SEC Form 4)
- CEO, GMPD Segment Mason Stephen M sold $8,274,117 worth of shares (35,000 units at $236.40), decreasing direct ownership by 66% to 18,061 units (SEC Form 4)
- CEO, PSS Segment Weitzman Deborah sold $1,731,524 worth of shares (7,354 units at $235.45), decreasing direct ownership by 9% to 77,901 units (SEC Form 4)
- Chief Financial Officer Alt Aaron E sold $9,926,140 worth of shares (42,000 units at $236.34), decreasing direct ownership by 67% to 20,495 units (SEC Form 4)
- Chief Legal/Compliance Officer Mayer Jessica L sold $6,952,485 worth of shares (29,436 units at $236.19), decreasing direct ownership by 47% to 33,076 units (SEC Form 4)
- Chief Information Officer Greene Michelle D. sold $2,746,187 worth of shares (11,650 units at $235.72), decreasing direct ownership by 53% to 10,330 units (SEC Form 4)
- RBC Capital Mkts initiated coverage on Cardinal Health with a new price target
- CEO, PSS Segment Weitzman Deborah was granted 7,314 shares and covered exercise/tax liability with 29,759 shares, decreasing direct ownership by 21% to 85,255 units (SEC Form 4) (for tax liability)
- CEO, GMPD Segment Mason Stephen M was granted 5,868 shares and covered exercise/tax liability with 25,289 shares, decreasing direct ownership by 27% to 53,061 units (SEC Form 4) (tax liability)
Latest SCNX
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
- SEC Form 10-Q filed by Scienture Holdings Inc.
- SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
- SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
- SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
- SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update